glp-1 agonists market Analogues Size to Hit USD 1,062.90 Billion by 2035 GLP-1 Drug Market: the rapid

Medicare Advantage plans have the broadest discretion in formulary design, and in 2026 that variability is especially pronounced for GLP-1 drugs

The current ASA guidelines are based on expert consensus rather than high-quality clinical evidence, and may not adequately address the perioperative risks posed by these medications

Voronova V, Zhudenkov K, Penland RC, Boulton DW, Helmlinger G, Peskov K

Athletes may therefore have difficulty accessing GLP-1RAs or be reluctant to speak on their experience using it, creating a lack of research in this area

Lopez LC, Frazier ML, Su CJ, Kumar A, Saunders GF

It produces butyrate, a short-chain fatty acid that may help keep the gut barrier strong and support healthy immune function